ClinicalTrials.gg

Program

ligufalimab

Also written as “AK117”, “Ivonescimab, AK117, Albumin-bound Paclitaxel, Gemcitabine” and “AK117 in combination with AK112”.

Its studies are mostly in Neoplasms · Myelodysplastic Syndromes · Leukemia, Myeloid, Acute · Triple Negative Breast Neoplasms · Pancreatic Neoplasms, led by Akeso.

Furthest: phase 3, since Aug 29, 202411 company-led studies, 8 open or runningNext primary completion: Dec 30, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Akeso118 open or runningphase 3since Aug 29, 2024Apr 14, 2020Dec 30, 2026phase 2 · NCT05227664

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 14, 2020First study: phase 1 study in NeoplasmsFirst studyNCT04349969 · 38 enrolled · Australia
  2. Jan 24, 2021Phase 1 study in NeoplasmsNCT04728334 · 49 enrolled · China
  3. May 19, 2021Phase 2 study in Myelodysplastic SyndromesNCT04900350 · 136 enrolled · China
  4. Jul 21, 2021Phase 2 study in Leukemia, Myeloid, AcuteNCT04980885 · 68 enrolled · China
  5. Jan 14, 20222 phase 2 studiesNCT05214482, NCT05227664
  6. Jul 17, 2023Phase 2 study in Resectable Gastric or Gastroesophageal Junction AdenocarcinomaNCT05960955 · 90 planned · China
  7. Dec 24, 2023Phase 2 study in Higher-risk Myelodysplastic SyndromesNCT06196203 · 90 planned · United States, China
  8. Apr 24, 2024Phase 2 study in Leukemia, Myeloid, AcuteNCT06387420 · 180 planned · China
  9. Aug 29, 2024Phase 3 study in Squamous Cell Carcinoma of Head and NeckNCT06601335 · 510 planned · China
  10. Apr 24, 2025Phase 3 study in Pancreatic NeoplasmsNCT06953999 · 999 planned · China

Ahead

  1. Dec 30, 2026Primary completion: phase 2 study in Triple Negative Breast NeoplasmsNCT05227664
  2. Jan 2027Primary completion: phase 3 study in Squamous Cell Carcinoma of Head and NeckNCT06601335
  3. May 14, 2027Primary completion: phase 3 study in Pancreatic NeoplasmsNCT06953999

TargetBeta

CD47 →read by rule
“A humanized immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen CD47, ”NCIt, by rule

Other programs on CD47

ProgramCompanyFurthest phaseStudies
evorpaceptrulealx-oncology-incphase 39
Anti-PD-1/CD47 Fusion Protein HX009rulehangzhou-hanx-biopharmaceuticals-ltdphase 25
CD47 Antagonist AUR103 CalciumruleDr. Reddy's Laboratoriesphase 22
1200mg of tqb2928 injectionSino Biopharmaceuticalphase 12

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06953999Pancreatic Neoplasms · China3RecruitingMay 14, 2027999
NCT06601335Squamous Cell Carcinoma of Head and Neck · China3RecruitingJan 2027510
NCT06387420Leukemia, Myeloid, Acute · China2Not yet recruitingApr 2026180
NCT06196203Higher-risk Myelodysplastic Syndromes · United States, China2RecruitingJan 202690
NCT05960955Resectable Gastric or Gastroesophageal Junction Adenocarcinoma · China2RecruitingNov 30, 202490
NCT05227664Triple Negative Breast Neoplasms · China2Active, not recruitingDec 30, 2026120
NCT05214482Advanced Malignant Tumors · China2CompletedNov 20, 2025154
NCT04980885Leukemia, Myeloid, Acute · China2Active, not recruitingSep 202568
NCT04900350Myelodysplastic Syndromes · China2Active, not recruitingSep 2025136
NCT04728334Neoplasms · China1CompletedJan 25, 202249
NCT04349969Neoplasms · Australia1CompletedNov 8, 202238

How it is read

Names in the registry

  • “AK117”, 9 entries
  • “Ivonescimab, AK117, Albumin-bound Paclitaxel, Gemcitabine”, 1 entry
  • “AK117 in combination with AK112”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.